NO931680L - Hepatitis c virus asialogly koproteiner - Google Patents

Hepatitis c virus asialogly koproteiner

Info

Publication number
NO931680L
NO931680L NO1993931680A NO931680A NO931680L NO 931680 L NO931680 L NO 931680L NO 1993931680 A NO1993931680 A NO 1993931680A NO 931680 A NO931680 A NO 931680A NO 931680 L NO931680 L NO 931680L
Authority
NO
Norway
Prior art keywords
virus
proteins
hepatitis
coproteines
asialogly
Prior art date
Application number
NO1993931680A
Other languages
English (en)
Other versions
NO304380B1 (no
NO931680D0 (no
Inventor
Robert O Ralston
Frank Marcus
Kent B Thudium
Barbara A Gervase
John A Hall
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO931680(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO931680D0 publication Critical patent/NO931680D0/no
Publication of NO931680L publication Critical patent/NO931680L/no
Publication of NO304380B1 publication Critical patent/NO304380B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO931680A 1990-11-08 1993-05-07 FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein NO304380B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61141990A 1990-11-08 1990-11-08
US61196590A 1990-11-08 1990-11-08
US75888091A 1991-09-13 1991-09-13
PCT/US1991/008272 WO1992008734A1 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins

Publications (3)

Publication Number Publication Date
NO931680D0 NO931680D0 (no) 1993-05-07
NO931680L true NO931680L (no) 1993-06-28
NO304380B1 NO304380B1 (no) 1998-12-07

Family

ID=27417050

Family Applications (2)

Application Number Title Priority Date Filing Date
NO931680A NO304380B1 (no) 1990-11-08 1993-05-07 FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein
NO972213A NO304381B1 (no) 1990-11-08 1997-05-14 FremgangsmÕte for fremstilling av hepatitt C-virus (HCV) og anvendelse derav i en immunoanalysemetode

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO972213A NO304381B1 (no) 1990-11-08 1997-05-14 FremgangsmÕte for fremstilling av hepatitt C-virus (HCV) og anvendelse derav i en immunoanalysemetode

Country Status (17)

Country Link
EP (2) EP0556292B2 (no)
JP (8) JPH06504431A (no)
AT (1) ATE188220T1 (no)
AU (1) AU668078B2 (no)
CA (2) CA2203443C (no)
CZ (1) CZ289006B6 (no)
DE (1) DE69131882T3 (no)
DK (2) DK0842947T4 (no)
ES (1) ES2139591T5 (no)
FI (1) FI107803B (no)
GR (1) GR3032771T3 (no)
HU (2) HUT66063A (no)
NO (2) NO304380B1 (no)
PT (2) PT99466B (no)
RO (1) RO115446B1 (no)
SK (3) SK285623B6 (no)
WO (1) WO1992008734A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
AU666176B2 (en) * 1992-01-31 1996-02-01 Abbott Laboratories Mammalian expression systems for HCV proteins
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
EP1845108A3 (en) 1994-07-29 2007-10-24 Innogenetics N.V. Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
ES2244965T3 (es) 1994-07-29 2005-12-16 Chiron Corporation Complejos e1/e2 secretados de virus de la hepatitis c obtenidos de polipeptidos e1 y e2 truncados en c-terminal.
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) * 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
JP4021493B2 (ja) 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CN100400101C (zh) 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2004016222A2 (en) * 2002-08-16 2004-02-26 Ohio University Hepatitis c viral-like particle purification
EP1888751A2 (en) 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
KR100206150B1 (ko) * 1990-04-04 1999-07-01 로버트 피. 블랙버언 항-에이치씨브이 항체에 대한 면역분석용 씨형 간염 바이러스(에이치디브이)항원의 조합체

Also Published As

Publication number Publication date
RO115446B1 (ro) 2000-02-28
ES2139591T5 (es) 2007-08-01
JP2001286290A (ja) 2001-10-16
PT102022B (pt) 2000-12-29
JP3207155B2 (ja) 2001-09-10
DK0842947T3 (da) 2004-07-26
DE69131882T3 (de) 2007-05-24
NO304381B1 (no) 1998-12-07
HU227498B1 (en) 2011-07-28
EP0556292B1 (en) 1999-12-29
JPH1171395A (ja) 1999-03-16
DE69131882D1 (en) 2000-02-03
DK0556292T4 (da) 2006-12-27
NO304380B1 (no) 1998-12-07
HU9301336D0 (en) 1993-10-28
DE69131882T2 (de) 2000-05-04
EP0842947B2 (en) 2009-03-18
JP4056306B2 (ja) 2008-03-05
JP2003174875A (ja) 2003-06-24
EP0556292B2 (en) 2006-11-29
ATE188220T1 (de) 2000-01-15
PT99466B (pt) 1999-04-30
DK0842947T4 (da) 2009-06-08
CA2095521A1 (en) 1992-05-09
HUT66063A (en) 1994-09-28
GR3032771T3 (en) 2000-06-30
JP2006219503A (ja) 2006-08-24
PT99466A (pt) 1992-10-30
CZ289006B6 (cs) 2001-10-17
EP0842947A3 (en) 2001-12-12
PT102022A (pt) 1999-01-29
AU9026791A (en) 1992-06-11
JP2003093081A (ja) 2003-04-02
EP0556292A4 (no) 1995-01-18
CZ82493A3 (en) 1994-04-13
SK44293A3 (en) 1993-08-11
SK285624B6 (sk) 2007-05-03
CA2095521C (en) 2009-06-30
SK285623B6 (sk) 2007-05-03
FI107803B (fi) 2001-10-15
ES2139591T3 (es) 2000-02-16
NO972213L (no) 1997-05-14
NO931680D0 (no) 1993-05-07
WO1992008734A1 (en) 1992-05-29
SK286106B6 (sk) 2008-03-05
FI932025L (fi) 1993-06-07
JP2008031181A (ja) 2008-02-14
JPH06504431A (ja) 1994-05-26
EP0842947A2 (en) 1998-05-20
DK0556292T3 (da) 2000-04-17
JP2005187479A (ja) 2005-07-14
CA2203443C (en) 2001-08-28
AU668078B2 (en) 1996-04-26
CA2203443A1 (en) 1992-05-09
NO972213D0 (no) 1997-05-14
SK69097A3 (en) 1997-11-05
EP0842947B1 (en) 2004-04-21
EP0556292A1 (en) 1993-08-25
FI932025A0 (fi) 1993-05-05

Similar Documents

Publication Publication Date Title
NO931680D0 (no) Hepatitis c virus asialogly koproteiner
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
EP0608261A4 (en) COMPOSITION OF AN IMMUNREACTIVE HEPATITIS C VIRUS POLYPEPTIDE.
AR241940A1 (es) Metodo para construir un vector de expresion recombinante de virus de polihedrosis nuclear de autographa californica, sintesis y purificiacion.
DE69535018D1 (de) Papillomavirus vakzine
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
EP0216564A3 (en) Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
ATE243755T1 (de) Rekombinente adenoviren-impfstoffe
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
EP1471073A3 (en) Hepatitis C virus asialoglycoproteins
FI971702L (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
EP0260090A3 (en) Expression of hepatitis b viral antigens from recombinant baculovirus vectors
KR890701745A (ko) O-결합 글리코실화가 감소된 바이러스 단백질
EP0385394A3 (en) Polyhedrin gene and genetic engineering thereof
EP0234862A3 (en) Expression of recombinant proteins in yeast

Legal Events

Date Code Title Description
MK1K Patent expired